Castle Biosciences (NASDAQ:CSTL) Shares Gap Down on Insider Selling

Key Points

• Insider sale: Director Derek J. Maetzold sold 3,622 shares under a pre-arranged Rule 10b5-1 plan for $25.10 each (≈$90,912), cutting his ownership by 59.14% and the stock gapped down from $25.10 to $23.59 on the news.
• Analyst sentiment: MarketBeat shows a "Moderate Buy" consensus (8 Buys, 1 Hold, 1 Sell) with a consensus price target of $46.14, while several firms have recently raised individual targets (e.g., Baird to $44, Lake Street to $52).
• Financial snapshot: Castle beat estimates last quarter (EPS -$0.08 vs. -$0.23; revenue $81.88M) but remains unprofitable with a negative net margin and an average sell-side forecast of -1.4 EPS for the year; market cap is about $722M.

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) gapped down prior to trading on Friday after an insider sold shares in the company. The stock had previously closed at $25.10, but opened at $23.59. Castle Biosciences shares last traded at $23.72, with a volume of 8,314 shares trading hands.

Specifically, insider Derek J. Maetzold sold 3,622 shares of the stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $25.10, for a total transaction of $90,912.20. Following the completion of the sale, the insider owned 2,502 shares of the company's stock, valued at $62,800.20. This represents a 59.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Zacks Research cut shares of Castle Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 2nd. Robert W. Baird increased their target price on shares of Castle Biosciences from $41.00 to $44.00 and gave the company an "outperform" rating in a research report on Friday, February 27th. Morgan Stanley raised shares of Castle Biosciences to a "buy" rating in a research report on Monday, March 2nd. Lake Street Capital increased their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the company a "buy" rating in a research report on Monday, January 12th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Castle Biosciences in a research report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.14.

Castle Biosciences Trading Up 0.6%

The stock's fifty day simple moving average is $26.64 and its 200-day simple moving average is $31.96. The firm has a market cap of $721.90 million, a PE ratio of -28.03 and a beta of 1.18. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.26 and a quick ratio of 5.11.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.15. The business had revenue of $81.88 million during the quarter, compared to analysts' expectations of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. On average, sell-side analysts forecast that Castle Biosciences, Inc. will post -1.4 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CSTL. AIGH Capital Management LLC acquired a new stake in shares of Castle Biosciences in the third quarter worth $16,105,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Castle Biosciences in the third quarter worth $615,000. SG Americas Securities LLC acquired a new stake in shares of Castle Biosciences in the third quarter worth $297,000. Portolan Capital Management LLC increased its stake in shares of Castle Biosciences by 1.7% in the third quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company's stock worth $34,499,000 after acquiring an additional 25,539 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Castle Biosciences in the third quarter worth $667,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.